Alcohol dehydrogenase mutant and application thereof in synthesis of drug intermediate

By designing the construction of alcohol dehydrogenase mutants and their recombinant plasmids and host cells, the limitations of reductase in the existing technology in the transformation and synthesis of different substrates are solved, and the alcohol dehydrogenase mutants are realized in ticagrelo Or the efficient catalysis of ticagrel intermediate compound I demonstrates huge potential for industrial application.

CN119060976APending Publication Date: 2024-12-03CHONGQING PUYOU BIOPHARMA CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411445627.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-16
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Reductases in the prior art can usually only be used in single substrate conversion and synthesis, and it is difficult to adapt to the needs of different chiral compounds, and different catalytic enzymes are needed.

Method used

An alcohol dehydrogenase mutant was designed, and its amino acid sequence was shown in SEQ ID NO:1. Through the construction of recombinant plasmids and host cells, the heterologous functional expression of the alcohol dehydrogenase mutant was achieved, and the Highly efficient catalytic activity was shown in the preparation of key intermediate compound I of Grelor or ticagrel.

Benefits of technology

This alcohol dehydrogenase mutant can be expressed in a stable heterologous and functional manner, has efficient catalytic activity, and has huge industrial application potential, becoming a universal alcohol dehydrogenase mutant that catalyzes different chiral configurations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060976A_ABST
    Figure CN119060976A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of enzyme engineering, in particular to an alcohol dehydrogenase mutant and application thereof in synthesis of drug intermediates, and the amino acid sequence of the alcohol dehydrogenase mutant is shown as SEQ ID NO: 1. The method comprises the following steps: culturing and crushing recombinant engineering bacteria, adding the recombinant engineering bacteria into a reaction system containing a substrate compound II, NAD < + >, ZnCl2, isopropanol, D-glucose and glucose dehydrogenase, and reacting to form a compound I; the reaction route is # imgabs0 #. The alcohol dehydrogenase mutant disclosed by the invention can stably realize heterologous functional expression, and meanwhile, the alcohol dehydrogenase mutant can show efficient catalytic activity in the preparation of a key intermediate compound I for pharmaceutical synthesis, and has huge industrial application potential; the mutant is expected to become a general alcohol dehydrogenase mutant for catalyzing different chiral configurations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of enzyme engineering, and specifically relates to an alcohol dehydrogenase mutant and application thereof. Background Art

[0002] Alcohol dehydrogenase is an important biocatalyst in the synthesis of chiral alcohol compounds as natural products and chiral drugs. Its application research has always been a hot topic for researchers in the field of enzyme engineering. Alcohol dehydrogenase can be used to construct chiral centers in the synthesis of chiral compounds. Different chiral compounds have significant differences in pharmacological activity, metabolism and toxicity. For chiral drugs, usually one of a group of enantiomers is active and effective, while the other is ineffective or even toxic.

[0003] Alcohol dehydrogenase plays an important role as a biocatalyst in biosynthesis. However, in the application of reductase, whether it can be heterologously expressed, the expression effect is good or bad, and whether it can effectively and efficiently catalyze the conversion of substrates into target optical chiral compounds all require specific analysis for specific issues.

[0004] For example, CN112522224A discloses an alcohol dehydrogenase mutant with improved activity and stereoselectivity, which is used for selectively catalyzing 2,6-dichloro-3-fluoroacetophenone to prepare (S)-1-(2,6-dichloro-3-fluorophenyl)ethanol. Another example is CN112852770A discloses an alcohol dehydrogenase mutant and its application in the preparation of chiral diaryl alcohol compounds by efficient asymmetric reduction. The alcohol dehydrogenase TbSADH was modified by directed evolution technology and methods to obtain a series of mutants with enzymatic activity on diaryl ketones represented by (4-chlorophenyl)pyridine-2-methanone.

[0005] At present, the reductase in the existing technology can often only play a single role in the conversion and synthesis of a certain substrate. Different catalytic enzymes must be constructed to meet the needs of different chiral compounds. Summary of the invention

[0006] The purpose of the present invention is to provide an alcohol dehydrogenase mutant and application thereof in synthesizing drug intermediates.

[0007] To achieve the above object, the present invention provides the following technical solutions:

[0008] An alcohol dehydrogenase mutant, whose amino acid sequence is shown in SEQ ID NO: 1, and whose nucleotide sequence of the encoding gene is shown in SEQ ID NO: 2.

[0009] The present invention also provides a recombinant plasmid, wherein the recombinant plasmid is connected to the DNA molecule shown in SEQ ID NO: 2. Preferably, the recombinant plasmid is a pET series plasmid.

[0010] The present invention also provides a host cell, wherein the host cell contains the above-mentioned recombinant plasmid. Preferably, the host cell is Escherichia coli.

[0011] The alcohol dehydrogenase mutant of the present invention can be used to synthesize drug intermediates. The specific method is: the recombinant engineering bacteria are cultured, crushed, and then added to a mixture containing substrate compound II, NAD + , ZnCl2, isopropanol, D-glucose, glucose dehydrogenase reaction system, the reaction forms compound I;

[0012]

[0013] The recombinant engineering bacteria is an E. coli that uses E. coli BL21 (DE3) as a host and pET-28a (+) as a vector to express the alcohol dehydrogenase mutant shown in SEQ ID NO: 1.

[0014] Among them, the H donor is the coenzyme NADH, and the coenzyme cycle is the coenzyme cycle catalyzed by glucose dehydrogenase. The reaction is as follows:

[0015]

[0016] The culture method of the recombinant engineered bacteria is as follows: the recombinant bacteria are inoculated into a culture medium, cultured overnight at 37°C with shaking, transferred to LB culture medium at an inoculum size of 1-5%, cultured at 37°C until OD600 = 0.6-0.8, add an inducer IPTG with a final concentration of 0.5 mM, induce at 16-25°C for 16 hours, and collect the bacteria by centrifugation. The recombinant engineered bacteria are crushed by ultrasonication, with an ultrasonic power of 260W, and an ultrasonic program of running for 3s, an interval of 5s, and a total duration of 3min.

[0017] The feeding mass ratio of the alcohol dehydrogenase mutant crude enzyme solution to the substrate is 1:0.1-10.

[0018] Compared with the prior art, the beneficial effects of the alcohol dehydrogenase mutant of the present invention and its application in the synthesis of drug intermediates include at least:

[0019] The present invention obtains a novel alcohol dehydrogenase mutant by a total synthesis method. The alcohol dehydrogenase mutant can stably express heterologous functionality. At the same time, the alcohol dehydrogenase mutant can exhibit efficient catalytic activity in the preparation of the key intermediate compound I of ticagrelor or ticagrelor, has great potential for industrial application, and is expected to become a universal alcohol dehydrogenase mutant catalyzing different chiral configurations. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Schematic diagram of the construction of recombinant plasmid. DETAILED DESCRIPTION

[0021] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] Example 1 Construction of alcohol dehydrogenase mutants

[0023] Upstream and downstream primers F and R of the alcohol dehydrogenase mutant were designed, and their sequences were shown in SEQ ID NO: 5-6. Using pUC57-D_001 constructed by total gene synthesis as a template, the D-001 gene containing BamH I and XhoI restriction sites was amplified by PCR.

[0024] Table 1 Primers

[0025] Primer name sequence serial number F GCGGGATCCATGAAAGCTATTCAGTACACCCG SEQ ID NO: 5 R CCGCTCGAGTTACAGACCCGGAACCACTACTGCA SEQ ID NO: 6

[0026] The PCR conditions were as follows: 98°C for 3 min, 98°C for 30 s, 55°C for 90 s, 72°C for 90 s, for 35 cycles.

[0027] PCR amplification system: 1.5 μL template, 1.5 μL upstream and downstream primers, 20.5 μL sterilized double distilled water, and 25 μL PrimerSTARMix.

[0028] The PCR product was purified and recovered using a gel recovery kit, and the concentration of the recovered product was tested by electrophoresis. The gel recovery product and pET-28a(+) plasmid (expression vector) were digested with BamH I and XhoI enzymes, and the gel recovery kit was used to purify and recover the gel recovery product after digestion. The gel recovery kit was used to purify and recover the plasmid after digestion, and the concentration of the recovered product was tested by electrophoresis.

[0029] The target gene D_001 was connected to the vector pET-28a(+). The connection system was as follows: 4 μL of the target gene, 2 μL of the vector pET-28a, 2 μL of the buffer, 1 μL of the ligase, and the connection was carried out at 16°C overnight. Figure 1 shown.

[0030] The constructed vector was introduced into E. coli BL21 (DE3) by chemical transformation technology, spread on LB plates containing kanamycin, and placed in a 37°C incubator overnight. The grown single colonies were subjected to plasmid extraction and sequencing, and finally recombinant engineered bacteria containing the alcohol dehydrogenase mutant gene were obtained.

[0031] The amino acid sequence of the alcohol dehydrogenase mutant is shown in SEQ ID NO: 1, and the nucleotide sequence of the alcohol dehydrogenase mutant is shown in SEQ ID NO: 2.

[0032] The formula of LB medium is: tryptone 10g / L, yeast powder 5g / L, NaCl 10g / L, pH 7.0.

[0033] Example 2 Preparation of alcohol dehydrogenase mutant fermentation broth

[0034] The recombinant engineered bacteria constructed in Example 1 were inoculated into 10 mL of LB medium and cultured at 37° C. with shaking overnight. The cells were transferred to LB medium at a 1% inoculum size and cultured at 37° C. until OD600 = 0.6. 50 μl of 0.5 mol / L IPTG was added and induced at 18° C. for 14 h. The cells were collected by centrifugation, washed with phosphate buffer (0.1 M) and resuspended. The cells were ultrasonically disrupted at a power of 260 W for 3 s, with an interval of 5 s for a total of 3 min to obtain a crude enzyme solution.

[0035] Example 3 Enzymatic Preparation of Compound I

[0036] 10 mL of crude alcohol dehydrogenase mutant enzyme solution obtained by crushing 1 g of alcohol dehydrogenase mutant wet cells prepared in Example 2 and 0.5 g of substrate compound II were added to a 250 mL Erlenmeyer flask and shaken. Subsequently, 0.1 mM ZnCl2, 200 μL 0.2 mg / mL NAD + and 1g D-glucose, 0.75g glucose dehydrogenase mutant enzyme powder (CAS#9028-53-9, purchased from Shangke Biopharmaceuticals (Shanghai)), and finally, the reaction system was fixed to 100mL (containing 20% ​​v / v isopropanol) with 50mM pH7.8 Tris-HCl buffer and shaken. The 100mL reaction system was placed on a shaker at 30°C and 220rpm for 16h to obtain the product compound I. The chiral purity of the product was 99.1%, the chemical purity was 90.7%, and the conversion rate was 93.6%.

[0037]

[0038] In order to highlight the beneficial effects of the present invention, the following comparative example experiments are given.

[0039] Comparative Example Preparation of Compound I by Wild-type Alcohol Dehydrogenase

[0040] Referring to the experimental methods of Examples 1 and 2 (the amino acid sequence of the wild-type alcohol dehydrogenase is shown in SEQ ID NO: 3, and the nucleotide sequence of the alcohol dehydrogenase mutant is shown in SEQ ID NO: 4), 10 mL of crude enzyme solution of the alcohol dehydrogenase mutant obtained by crushing 1 g of the alcohol dehydrogenase wild-type wet bacteria and 0.5 g of substrate compound II were added to a 250 mL Erlenmeyer flask and shaken. Subsequently, 0.1 mM ZnCl2, 200 μL 0.2 mg / mL NAD + and 1g D-glucose, 0.75g glucose dehydrogenase mutant enzyme powder (CAS#9028-53-9, purchased from Shangke Biopharmaceuticals (Shanghai)), and finally, the reaction system was fixed to 100mL (containing 20% ​​v / v isopropanol) with 50mM pH7.8 Tris-HCl buffer and shaken. The 100mL reaction system was placed on a shaker at 30°C and 220rpm for 16h to obtain the product compound I. After testing, the product conversion rate was 49.3%.

[0041] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. An alcohol dehydrogenase mutant, Features: Its amino acid sequence is shown in SEQ ID NO:

1.

2. The alcohol dehydrogenase mutant according to claim 1, Features: The nucleotide sequence of the coding gene is shown in SEQ ID NO:

2.

3. A recombinant plasmid, Features: The recombinant plasmid is connected to the DNA molecule shown in SEQ ID NO:

2.

4. The recombinant plasmid according to claim 3, Features: The recombinant plasmid is a pET series plasmid.

5. A host cell, Features: The host cell contains the recombinant plasmid according to claim 3 or 4.

6. The host cell according to claim 5, Features: The host cell is Escherichia coli.

7. Use of the alcohol dehydrogenase mutant according to claim 1 or 2 in the synthesis of pharmaceutical intermediates, Features: The recombinant engineered bacteria were cultured, broken, and added to the substrate compound II and NAD + 、ZnCl 2 , isopropanol, D-glucose, glucose dehydrogenase reaction system, the reaction forms compound I; The recombinant engineering bacteria is E. coli, which uses E. coli BL21 (DE3) as a host and pET-28a (+) as a vector, and expresses the alcohol dehydrogenase mutant shown in SEQ ID NO:

1.

8. Use of the alcohol dehydrogenase mutant according to claim 7 in the synthesis of pharmaceutical intermediates, Features: The H donor is the coenzyme NADH, and the coenzyme cycle is catalyzed by glucose dehydrogenase. The reaction is as follows:

9. Use of the alcohol dehydrogenase mutant according to claim 7 in the synthesis of pharmaceutical intermediates, Features: The culture method of the recombinant engineered bacteria is as follows: the recombinant bacteria are inoculated into a culture medium, cultured at 37° C. with shaking overnight, transferred into LB culture medium at an inoculation rate of 1-5%, cultured at 37° C. until OD600=0.6-0.8, added with an inducer IPTG at a final concentration of 0.5 mM, induced at 16-25° C. for 16 hours, and collected the bacteria by centrifugation.

10. Use of the alcohol dehydrogenase mutant according to claim 7 in synthesizing pharmaceutical intermediates, Features: The feeding mass ratio of the alcohol dehydrogenase mutant wet bacteria to the substrate is 1:0.1-10.

Citation Information

Cited By

  • Totally-synthesized ketoreductase and application thereof

    CN120519414A